Novartis’ Tasigna Beats Gleevec in Leukemia Study

Novartis AG, whose best-selling cancer medicine Gleevec loses patent protection as early as 2015, said the drug’s successor Tasigna worked better to treat newly diagnosed leukemia after two years.
Bloomberg